BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96…